Abstract
Photodynamic therapy (PDT) uses light-activated drugs to treat diseases ranging from cancer to age-related macular degeneration and antibiotic-resistant infections. The finite penetration depth of light has limited the clinical application of PDT. This work investigates the substitution of light in PDT using Cerenkov light induced by 45MV photon beams from the LA45 therapy accelerator. This new treatment technique has been named radio-dynamic therapy (RDT) and this paper investigates the dosimetric requirement of RDT. Cerenkov light and its spectrum induced by 45MV x-ray beams from a LA45 therapy accelerator, was simulated with the Monte Carlo method. The excitation efficiency of Cerenkov light in RDT was theoretically studied and compared with the excitation efficiency of external laser light in PDT. Experiments were carried out to enhance the excitation efficiency for singlet oxygen production with specific coenzymes as substrates.
Introduction
Photodynamic Therapy (PDT) is a clinically proven method that uses photosensitizers to produce singlet oxygen, destroying cancer cells. However, PDT faces a significant "depth problem": visible light, typically red lasers at 630nm, penetrates only about 7mm into human tissue. This restricts its use to superficial cancers or necessitates invasive probes. Radio-Dynamic Therapy (RDT) aims to overcome this by generating Cerenkov light—the blue glow produced when charged particles exceed the speed of light in a medium—directly within deep-seated tumors using high-energy 45MV X-ray beams.
Methods
The study utilized a multi-pronged validation approach:
- Monte Carlo Simulations: The GEANT4 toolkit was used to simulate 5MV and 45MV photon beams in a water phantom, calculating the quantity and energy spectra of produced Cerenkov photons.
- Theoretical Analysis: Excitation efficiency was compared between internal Cerenkov light and traditional external lasers, focusing on spectral overlap with drug absorption peaks.
- Biochemical Experiments: Singlet oxygen production was measured using Protoporphyrin IX (PpIX) and a fluorescent marker (DMA). A coenzyme catalyst ($H_2O_2$) was added to boost the therapeutic effect.
- Equipment: A specialized LA45 racetrack accelerator provided the 45MV X-rays, significantly higher than standard 6MV clinical beams.
Results and Discussion
The Cerenkov Mechanism and the 45MV Threshold
Simulations revealed that the number of Cerenkov photons produced per incident particle increases significantly with energy. The 45MV beam produced a Cerenkov intensity 5.54 times higher than a 5MV beam. This high energy also triggers photonuclear reactions, resulting in a "slow component" of light emission that persists after the beam is deactivated.
Spectral Matching and the Soret-Band Advantage
A key advantage of RDT is the spectral match between Cerenkov light and the photosensitizer. While traditional PDT uses 630nm light for penetration, PpIX is 10–20 times more sensitive to UV/blue light (370–430nm), known as the Soret band. Cerenkov light naturally peaks in this range, making it inherently more efficient.
Theoretical calculations indicate that radiation-induced Cerenkov light is approximately 15 times more effective at activating PpIX than the 630nm laser light used in conventional PDT.
Synergetic Therapeutic Effects
RDT combines the direct cell-killing power of radiotherapy with the biochemical action of PDT. By using the tumor itself as a "homogeneous internal light source," RDT avoids the exponential attenuation seen with external lasers. Furthermore, the addition of a coenzyme substrate increased singlet oxygen production by up to 5 times, compensating for the lower absolute intensity of Cerenkov light compared to high-power lasers.
Conclusion
RDT represents a promising evolution of photodynamic therapy, potentially enabling the treatment of deep-seated tumors without invasive light delivery. While further in vivo validation and precise dosimetric modeling are required, the physical and biochemical foundations established here suggest that 45MV X-ray beams can effectively drive therapeutic photosensitization throughout a treatment volume.
Summary updated